BELITE BIO, INC
Belite Bio is a clinical-stage biopharmaceutical company headquartered in San Diego, California. It develops therapies for people with degenerative retinal diseases and metabolic diseases. Its lead drug candidate, tinlarebant, also known as LBS-008, is an oral tablet intended to treat Stargardt disease type 1 and geographic atrophy, a late form of dry age-related macular degeneration. Belite Bio is conducting clinical trials of tinlarebant for both retinal diseases. Its pipeline also includes LBS-009, an oral compound intended to treat metabolic diseases including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes and gout. The company holds a worldwide exclusive license from Columbia University for the intellectual property portfolio used to develop tinlarebant.
No SEC Form 4 filings for $BLTE in the last 30 days.
See all $BLTE insider activity →Belite Bio (BLTE) reported a Q3 2026 net loss of $30.3M, up from $21.7M in Q3 2025. The company's cash reserves decreased to $271.3M from $352.9M at year-end 2025. The FDA granted priority review for tinlarebant, with a PDUFA target date of February 12, 2027. Belite also submitted applications in Japan and other countries. The company will host a conference call on November 12, 2026.
Belite Bio (BLTE) has moved its securities listing to the Nasdaq Global Select Market, the highest tier, starting today. The company met the market's financial and liquidity standards. Belite Bio is a clinical-stage drug developer focusing on retinal diseases, with key trials ongoing for its lead candidate, tinlarebant.
H.C. Wainwright maintained a $245 price target for Belite Bio (BLTE) after regulatory submissions in three countries. The stock is up 88% over the past year, with analysts showing strong optimism. Belite Bio submitted applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company aims for a global launch, with a first-mover advantage if approved.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BLTE (BELITE BIO, INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent BLTE coverage spans financial news, regulation and insider activity.
The widened loss and cash decline increase short‑term risk, while the FDA priority review could be a catalyst if approval is granted.
Uplisting may improve liquidity and attract institutional interest, supporting a modest price gain.
Analyst upgrade and regulatory milestones suggest upside potential.
Regulatory submissions for a rare‑disease therapy can lift the stock if approvals are granted, but pending outcomes keep risk elevated.
Positive Phase III results suggest potential regulatory approval and commercial launch.
AlphAI scores every news story that mentions BLTE with an AI model for sentiment and relevance, and aggregates insider trades from BELITE BIO, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Belite Bio (BLTE) reported a Q3 2026 net loss of $30.3M, up from $21.7M in Q3 2025. The company's cash reserves decreased to $271.3M from $352.9M at year-end 2025. The FDA granted priority review for tinlarebant, with a PDUFA target date of February 12, 2027. Belite also submitted applications in Japan and other countries. The company will host a conference call on November 12, 2026.
Belite Bio (BLTE) has moved its securities listing to the Nasdaq Global Select Market, the highest tier, starting today. The company met the market's financial and liquidity standards. Belite Bio is a clinical-stage drug developer focusing on retinal diseases, with key trials ongoing for its lead candidate, tinlarebant.
H.C. Wainwright maintained a $245 price target for Belite Bio (BLTE) after regulatory submissions in three countries. The stock is up 88% over the past year, with analysts showing strong optimism. Belite Bio submitted applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company aims for a global launch, with a first-mover advantage if approved.
Belite Bio (BLTE) submitted Marketing Authorization Applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company also filed applications in the US and Japan, with the US application receiving Priority Review. Tinlarebant met its primary endpoint in a Phase 3 trial and has received several regulatory designations.
Belite Bio (BLTE) presented at the Morgan Stanley conference, highlighting its drug tinlarebant for Stargardt disease. The company cited strong Phase III data, a 36% reduction in lesion progression, and a February 12 PDUFA date. Shares rose 2.35% in after-hours trading to $177.88. The company also discussed its commercial strategy and Japan filing.
On September 9, 2026, significant insider trading activity was reported. Alumis Inc. (ALMS) director acquired $10.7M in shares, while NVIDIA (NVDA) director sold $235.6M. Greenwave (GWAV) CEO bought $8M in shares, and BELITE BIO (BLTE) executives sold $31.9M. Workday (WDAY) director sold $17.9M in shares. Dell (DELL) insiders sold $48.1M. Inhibrx (INBX) and Cytosorbents (CTSO) directors also made notable purchases.
Lin Yu-Hsin (Chief Executive Officer) sold 100,435 shares of BELITE BIO, INC (BLTE) at an average of $190.00 ($180.29–$198.09, $19.08M total) across 19 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.
Chuang Hao-Yuan (Chief Financial Officer) sold 67,395 shares of BELITE BIO, INC (BLTE) at an average of $189.98 ($180.16–$198.05, $12.80M total) across 19 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.
US equities show divergence with semiconductor and biotech stocks rising, while software stocks fall. Belite Bio (BLTE) and Aehr Test Systems (AEHR) lead gains, while Guidewire Software (GWRE) and lululemon (LULU) lead declines. SanDisk (SNDK), Cohu (COHU), and Cerebras Systems (CBRS) also see notable gains. Fair Isaac (FICO), UiPath (PATH), and Asana (ASAN) experience significant drops.
Belite Bio (BLTE) shares rose 9.0% after the FDA granted priority review to its new drug application for tinlarebant, a treatment for Stargardt disease. The company expects a decision by February 12, 2027, and is preparing for commercial launch, targeting 53,000 patients. Phase III data showed a 35.7% reduction in lesion growth versus placebo. The company projects $563.2 million revenue and $318.3 million earnings by 2029, a 24% upside to its current price.
